Unlike previous years, the annual neurology congress of Iran was conducted in the form of a virtual webinar due to the coronavirus pandemic. During this virtual congress, Medisa Ara Gostar Company, KMT Holding Pharmaceutical Department held a webinar to cover updates of cannabidiol (CBD) in treatment of neurological diseases, on 1 January 2021.
Prominent professors, Dr. Seyed Massoud Nabavi, Dr. Mehran Ghaffari, Dr. Majdi Nasab and Dr. Marjan Asadollahi participated in this specialized congress.
During the webinar, the therapeutic potential of CBD in treatment of movement disorders, especially Multiple Sclerosis (MS) was interpreted in detail.
The inaugural speech was performed by Dr. Massoud Nabavi about the clinical indications of cannabinoids in neurological disorders.
Afterwards, the CBD’s potential in reducing the symptoms of Multiple sclerosis (MS) such as neuropathic pain, spasticity, fatigue, urinary incontinence and sleep disorders was expatiated by Dr. Ghaffari.
Subsequently, Dr. Majdi Nasab highlighted the cannabidiol’s impacts on anxiety reduction and sleep regulation.
Eventually, Dr. Marjan Asadollahi delineated the therapeutic efficacy of Cannabidiol in treatment of seizures and epilepsy, especially drug-resistant epilepsies such as Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
The event was ended with introduction of Inovo Lipomed CBD® as the first CBD-based liposomal supplement in Iran. In the meanwhile, a question and answer session was accomplished under the supervision of Dr. Nabavi between the esteemed professors and attendees.